Study guide
3.11 Family Planning & Reproductive Options
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
3.11 Family Planning & Reproductive Options
Key Takeaways Explain This Topic AI
After genetic risk is identified, standard options include prenatal diagnosis in a spontaneous pregnancy, IVF with PGT, use of donor gametes or embryos, adoption, pursuing pregnancy without genetic testing, and choosing not to have (more) children
Non-directive counseling presents accurate risks, benefits, limitations, and logistics of each path without steering the patient toward the counselor’s preferred reproductive outcome
Option selection depends on condition severity/penetrance, inheritance, residual risk, values, religion/culture, finances, timing, and tolerance for uncertainty—not on a single “correct” medical choice
Donor gametes remove the contribution of the at-risk parental genome for that gamete type but introduce third-party reproduction counseling, identity, and disclosure considerations
Documenting the decision-making process, offering time-limited follow-up, and revisiting options as life circumstances change are core genetic counseling competencies in Domain 3C
Last updated: August 2026
3.11 Family Planning & Reproductive Options
Quick Answer: After risk is identified, families may choose prenatal diagnosis , IVF ± PGT , donor sperm/eggs/embryos , adoption , pregnancy without genetic testing , or not having (additional) children . Counselors present each option’s risk, residual uncertainty, timing, and psychosocial implications in a non-directive frame—supporting informed choice rather than prescribing a single reproductive outcome.
Domain 3C scores whether you can generate a complete option set, tailor it to inheritance and condition facts, and avoid coercive language. Application/analysis items often hinge on what was omitted (e.g., forgetting donor gametes) or on directive slips (“You should do PGT”).
Why Option Counseling Is Its Own Skill
Identifying a pathogenic variant, carrier status, or chromosomal rearrangement answers a medical genetics question; it does not dictate reproduction. Two couples with identical molecular risk may choose opposite paths. Your job is to make each path intelligible and accessible , then support the decision that fits the clients’ goals.
Non-directive does not mean:
- Withholding medical facts or test limitations
- Refusing to correct misconceptions
- Pretending all options are equally available or equally suited to every medical indication
Non-directive does mean:
- Not privileging your personal reproductive values
- Not equating “good patient” with pursuing maximal genetic testing
- Checking understanding and decision consistency with stated values
- The Core Reproductive Option Menu
Option What it addresses Key residual issues to name
Spontaneous conception + prenatal diagnosis (CVS/amnio ± molecular/CMA/karyotype) Diagnostic information about this pregnancy Procedure-related risks; timing; possible mosaic/uncertain results; decisions about continuation
Spontaneous conception + prenatal screening only (NIPT/serum/ultrasound) Risk modification, not diagnosis False positives/negatives; does not replace diagnostic testing for high prior risk monogenic disease
IVF with PGT-M/PGT-SR (± PGT-A) Embryo selection before pregnancy Cycle failure; mosaic/uninformative results; cost; does not guarantee healthy child; confirmatory prenatal testing may still be offered
Donor sperm / donor eggs / donor embryos Removes at-risk gamete contribution for that parent Third-party identity, disclosure to child, donor screening limits, legal parentage
Adoption (or embryo adoption where available) Parenting without shared-genome risk from the couple’s gametes Access, cost, uncertainty of child’s genetics, psychosocial transition
Conceive / continue without genetic testing Autonomy to decline information Residual recurrence risk unchanged; plan for newborn evaluation if relevant
Remain child-free / no further pregnancies Avoids reproductive genetic risk entirely Grief, relationship, and identity work—still a valid informed choice
Prenatal treatment / specialized fetal therapy (condition-specific, uncommon) Rare pathways (e.g., certain inborn errors with fetal therapy protocols) Experimental vs established; center-specific—do not invent availability
Exam trap: Listing only “test or don’t test” when the vignette asks for reproductive options after a positive carrier screen. Boards expect the full menu , including third-party reproduction and adoption where relevant.
- Matching Options to Genetic Context
- Autosomal recessive carrier couple
Both partners carry pathogenic variants in the same gene → 25% risk of affected offspring each pregnancy (for fully penetrant childhood disorders). Options commonly discussed: prenatal diagnosis of the familial variants; IVF/PGT-M; donor gamete from a non-carrier (or screened) donor; adoption; untested pregnancy with acceptance of 25% risk; child-free.
Autosomal dominant affected parent
50% transmission risk (adjusted for penetrance/expressivity). Prenatal diagnosis or PGT-M for the known variant; donor gamete from the unaffected partner’s side as applicable (donor egg if maternal AD condition and egg donation chosen, etc.); adoption; decline testing.
X-linked (e.g., female carrier)
Discuss sex-based empiric risks, prenatal diagnosis, PGT-M, and limitations of sex selection alone if the goal is avoiding affected offspring (sex selection without genotype still leaves carrier females and does not address all scenarios).
Balanced translocation carrier
Emphasize empiric risks of miscarriage and unbalanced offspring; PGT-SR; prenatal diagnosis with karyotype/CMA as indicated; donor gametes; adoption.
Uncertain results (VUS, mosaic PGT, inconclusive NIPT)
Option counseling must not treat uncertain genotypes as established diagnoses. Management may focus on phenotype-driven care, additional testing, or proceeding with explicit acknowledgment of uncertainty.
Worked Counseling Scenario
A couple learns they are both carriers for a severe infantile autosomal recessive condition after expanded carrier screening. They want children within two years, have insurance with partial IVF coverage, and state that terminating an affected pregnancy would conflict with their values, but they also fear raising a child with the disorder.
High-yield counseling moves:
Restate residual risk without testing (25% each pregnancy) and what “affected” means clinically.
Map options to values: PGT-M aligns with avoiding termination while reducing affected transfers; donor gametes also avoid the 25% risk without prenatal diagnosis decisions; adoption separates parenting from the molecular risk; declining all testing honors autonomy with eyes open.
Name tradeoffs: PGT requires ART logistics and possible multiple cycles; donor gametes change genetic relatedness; prenatal diagnosis is less useful if termination is unacceptable—though some still want information for preparation.
Avoid steering: “Given what you shared about termination and about the condition’s severity, families in your situation often compare PGT-M and donor gametes—would you like details on both?” is facilitative; “You should do IVF” is directive.
Psychosocial and Access Layers
Reproductive genetics decisions intersect with:
- Religion and culture (views on embryos, termination, third-party gametes)
- Cost and geography (IVF/PGT access; Medicaid variability)
- Relationship dynamics and blame after carrier results
- Disability perspectives and lived experience of the condition in the family
- Timing (age-related fertility, urgent transplant or oncology fertility preservation contexts)
Offer written summaries, decision aids when available, and follow-up visits. Revisit options after a failed IVF cycle, a miscarriage, or a change in relationship status—preferences are not static.
Documentation and Team Communication
Chart the options reviewed, client understanding, decisions made and deferred , and referrals (REI, prenatal diagnosis clinic, adoption resources, mental health). Coordinate language with reproductive endocrinology and MFM so the family does not hear contradictory “shoulds.”
Master the complete option set plus non-directive application —Domain 3C frequently tests both content completeness and counseling stance.